Alkermes
immune modulation portfolio of engineered technical challenge alkermes protein engineering solution key anti tumor mechanisms alfa tumor targeted split enhanced efficacy efficacy of limited by expansion of cells and other undesirable effects fusion of circularly permuted with the subunit resulting in only activating intermediate affinity has low tolerability when given systemically efficacy of limited by a protein that binds to separate inactive tumor targeted engineered for which activity is not subunits assemble and activate in the tumor blocked by suppressive mechanisms expansion of cells and cells minimal expansion of cells drive responses at the tumor site through potent activation of and cells enhance mediated anti cancer immune responses reduce cell exhaustion potential cancer types solid tumors including melanoma platinum resistant ovarian cancer solid tumors including pancreatic breast colon and ovarian cancer tumor inhibitor resistant tumors | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
101 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Investor Day
March 2021
immune modulation portfolio of engineered technical challenge alkermes protein engineering solution key anti tumor mechanisms alfa tumor targeted split enhanced efficacy efficacy of limited by expansion of cells and other undesirable effects fusion of circularly permuted with the subunit resulting in only activating intermediate affinity has low tolerability when given systemically efficacy of limited by a protein that binds to separate inactive tumor targeted engineered for which activity is not subunits assemble and activate in the tumor blocked by suppressive mechanisms expansion of cells and cells minimal expansion of cells drive responses at the tumor site through potent activation of and cells enhance mediated anti cancer immune responses reduce cell exhaustion potential cancer types solid tumors including melanoma platinum resistant ovarian cancer solid tumors including pancreatic breast colon and ovarian cancer tumor inhibitor resistant tumors | Alkermes
Investor Day
March 2021
immune modulation portfolio of engineered technical challenge alkermes protein engineering solution key anti tumor mechanisms alfa tumor targeted split enhanced efficacy efficacy of limited by expansion of cells and other undesirable effects fusion of circularly permuted with the subunit resulting in only activating intermediate affinity has low tolerability when given systemically efficacy of limited by a protein that binds to separate inactive tumor targeted engineered for which activity is not subunits assemble and activate in the tumor blocked by suppressive mechanisms expansion of cells and cells minimal expansion of cells drive responses at the tumor site through potent activation of and cells enhance mediated anti cancer immune responses reduce cell exhaustion potential cancer types solid tumors including melanoma platinum resistant ovarian cancer solid tumors including pancreatic breast colon and ovarian cancer tumor inhibitor resistant tumors | Alkermes
Related slides by other companies
Absci
Investor Presentation
July 2023
antibodies selected in tertiary lymphoid structures bind to cancer cells and are associated with favorable clinical outcomes | Absci
Immix Biopharma
Investor Presentation
November 2023
potential to disrupt the oncology and immunology categories | Immix Biopharma
SentiBio
SPAC
October 2021
not logic gate functions in to specifically kill cancer cells and spare healthy cells a sie | SentiBio
SentiBio
SPAC
October 2021
armed car cells exhibit significantly improved killing of cancer cells a in tumor cell day post culture ratio i | SentiBio
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io